Acute Respiratory Distress Syndrome – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed events of ARDS for each country, as well as annualized events projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s ARDS forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ARDS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the diagnosed events of ARDS for each forecast year, Clarivate Epidemiology provides forecast data for the following subpopulations:
- Diagnosed events by severity
- Diagnosed events by type of pulmonary injury
- Diagnosed events of ARDS: sepsis-related vs non-sepsis related
Note: Coverage may vary by country.
Table of contents
- Acute Respiratory Distress Syndrome - Epidemiology - Mature Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of acute respiratory distress syndrome)
- Diagnosed events
- Diagnosed events by severity
- Diagnosed events by type of pulmonary injury
- Sepsis-related and non-sepsis-related diagnosed events
- Risk/protective factors applied to disease forecast models
- Reference Materials
